| INTRODUC TI ON
Hepatitis C virus (HCV) infection is one of the leading causes of liver morbidity and mortality worldwide. It affects 2% of the population, being the leading global indication for liver transplant. However, while some patients have a rapidly progressive disease course, less than half of those chronically infected will go on to develop liver cirrhosis after 30 years of infection. The influences on disease progression are incompletely understood although environmental, viral and genetic variables have been shown to accelerate liver fibrosis.
With the advent of effective but expensive direct acting antiviral (DAA) therapies for HCV, identifying those at the highest risk of liver disease progression is necessary to optimize the cost utility of such therapies, which can vary greatly between individual clinical scenarios. One factor consistently associated with poorer outcome is the presence of additional liver pathologies. [1] [2] [3] As detailed in the AASLD/ IDSA guidance on HCV treatment, these include alcohol excess and active coinfection with other hepatotropic viruses such as hepatitis B virus (HBV). 3 The majority of adults exposed to HBV will clear the virus from their serum. Despite this, HBV DNA has the potential to remain in hepatocytes as covalent closed circular DNA (cccDNA) long after viremia has resolved. 4 The effect of previous HBV infection on HCV-associated liver disease has not yet been determined.
In the event of acute infection with HBV, 95% of healthy adults will appear to clear the infection with undetectable hepatitis B surface antigen (HBsAg) and development of hepatitis B surface antibodies (HBsAb) and hepatitis B core antigen (HBcAb) with undetectable serum HBV DNA using commercial assays. However, in the liver, HBV cccDNA has the potential to persist in hepatocytes for many years. 4 The replicative potential of this "occult" HBV DNA is well recognized as HBV reactivation, following immunosuppression is not uncommon. Indeed, for those with evidence of previous HBV infection undergoing immunosuppressive therapy, guidelines now recommend active monitoring and prophylactic antiviral therapy.
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The prevalence of DNA persistence in hepatocytes, also termed occult HBV infection (OBI) following viral clearance, is unknown. For those with serological markers of previous infection such as HBcAb and HBV DNA, prevalence varies depending on the sensitivity of testing. Several papers have highlighted a link between OBI and poor liver outcomes. This has been predominantly reported in the context of chronic HCV where detection of HBV DNA in the liver is associated with accelerated liver fibrosis, increased risk of hepatocellular carcinoma (HCC) and lower response rates to dual HCV therapy. [6] [7] [8] [9] A study using nested HBV PCR in liver biopsies of HCV-positive, HBsAg-negative patients to detect OBI revealed more severe liver disease in the OBI-positive group. 10 Recent meta-analyses have concluded that OBI significantly increases the risk of chronic liver disease and HCC. 11 However, most of the analyses included in these studies are small and in selected population. In addition, previous research has not had sufficient power to correct for possible confounding factors such as alcohol abuse and HCV genotype, which have been shown to influence clinical outcomes in chronic HCV infection.
Determining the impact of PCR-proven OBI in a large population of patients with HCV would be impractical, particularly as liver biopsy has been largely replaced by noninvasive methods in the routine assessment of HCV liver disease. However, it should be possi- 
| Study design and statistical analyses

| Univariate and multivariate analyses
Univariate analyses ( those who did not due to screening. As date at the first appointment was used as the starting time point, PWID would tend to be younger at the start of follow-up and had a longer time to events interested.
Violation of proportional hazards assumptions was not found in any of the multivariate models.
| D ISCUSS I ON
Our data suggested a strong link between serological evidence of previous HBV infection and development of decompensated cirrhosis and HCC in patients with HCV. This association remains significant event once confounders such as history of alcohol excess, IDU, age at the first clinic appointment and smoking history have been taken into account. This is the largest study to confirm that previous HBV infection is an important factor in HCV liver disease outcomes, which may also have implications for other liver conditions.
Within Scotland, the majority of individuals who do become infected with HCV take part in risk-prone behaviours such as IDU or are immigrants from highly endemic areas. Such individuals are also The means by which coinfection induces higher levels of cellular damage are incompletely understood. However, there is evidence that HBV and HCV have shared mechanisms for inducing cellular stress which could become synergistic in the presence of both viruses to enhance fibrogenesis. 23 In addition, upregulation of proto-oncogenes are seen in both HBV and HCV, which may predispose to liver damage and eventually HCC. 24 While we did not demonstrate a significant association between HBsAg positivity and adverse outcomes, these associations have been reported elsewhere and we did find a trend towards adverse outcomes and it is likely that we were unable to detect an association due to the relatively small number of patients and events in this group in our cohort.
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Our study hinges on using HBcAb as a surrogate for OBI. In the setting of chronic HBV infection, HBcAb has a specificity of above 95% and an overall accuracy of 90% as a surrogate marker for ever infection; 25 we can assume that of those testing positive for HBcAb, at least 95% will have been exposed to HBV. Association of outcomes with previous infection may be weakened by individuals who lose HBcAb over time; however, this does not introduce risk of a type I error in our study. The use of HBcAb to determine OBI is less clear-cut. It has been found that HBcAb has a sensitivity of 54% and specificity of 72% for OBI in a HCV-positive population, with a positive predictive value of 56%. 10 Similarly, another study found that 62% of those with HBcAb had evidence of viral DNA in their liver. 26 It must be remembered that extracting cccDNA from liver tissue that has been stored in various conditions for retrospective analysis is not a "gold standard," and thus, more patients with 
| Vaccination uptake and efficacy
There were insufficient clinical data to determine whether any of those with positive HBcAb status had taken up vaccination which was subsequently unsuccessful, with or without the influence of advanced liver disease. However, rates of vaccine efficacy are almost 90% in those with compensated cirrhosis and higher in those without significant liver disease. 29 Given the low rates of vaccine uptake in PWID population, it is improbable that the association between HBcAb and cirrhosis is due to vaccine nonresponse, and then, subsequent infection with HBV is already in cirrhotic individuals.
While it is possible that those exposed to HBV have riskier behaviours, a study of Australian PWID shows that individuals who are unvaccinated against HBV are more likely to be male and do not have more high-risk patterns of drug use. 30 To explore this hypothesis in the Scottish population, we also analysed the relationship between HBV status and all-cause mortality. This analysis showed a strong association between IDU and mortality but no significant increase in all-cause mortality risk with HBcAb positivity (Table 4) .
A subanalysis of the HBcAb-negative cohort was also performed to determine any differences between those with evidence of vaccination (HBsAb positive) and those without (Table 5) . In this cohort, vaccinated individuals were more likely to be younger, male, Caucasian, having a history of IDU and be smokers compared to unvaccinated individuals (P < .001 for these characteristics). In addition to the 18.5% of the HCV population known to be exposed to HBV, 62% of the Scottish HCV population had not been vaccinated at the point of presenting with HCV, which suggests that historically, the UK vaccination policy was failing to adequately protect individuals at risk of HBV.
| Implications for hepatitis C virus therapy
Although recent guidance of National Institute for Health and Care
Excellence has suggested that direct acting antivirals can be used for all HCV-infected patients with genotype 1 infection, the cost of provision for all HCV-infected individuals will be considerable. Ideally, healthcare providers should prioritize treatment for patients where this will result in the biggest improvement in health outcomes. Early access programmes in the UK have largely been targeted at those with more advanced disease. Identifying individuals whose liver disease may progress more rapidly, for example those with previous HBV exposure, may help target those who will benefit most from treatment in earlier stages of the disease.
| Limitations of analysis
One common limitation encountered in observational research in presence of other liver pathologies, we chose not to include it in this study. 
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